Login to Your Account



Phase III Revlimid Trial Halted; Celgene's Stock Suffers Drop

By Kim Coghill


Thursday, April 29, 2004
Despite Celgene Corp.'s low expectations regarding Revlimid's ability as a monotherapy in the difficult indication of metastatic malignant melanoma patients who already had failed two lines of therapy, the firm's stock dipped on stopping a Phase III trial in that indication. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription